Industrial Policy & Trade Monitor· 2662 actions· ✨ 89 recent

The Office of the United States Trade Representative released the 2026 Special 301 Report on 30 April 2026, designating Vietnam as a Priority Foreign Country (PFC) — the most severe category under Section 182 of the Trade Act of 1974 (19 U.S.C. § 2242). This is the first PFC designation since Ukraine held the status from 2013 through 2015, a gap of approximately 11 years. The PFC designation triggers a statutory 30-day window (expiring ~30 May 2026) within which USTR must decide whether to initiate a Section 301 investigation under 19 U.S.C. § 2412(b)(2)(A), which could lead to tariffs, withdrawal of trade benefits, or other Section 301 enforcement remedies against Vietnam. Separately, the EU was added to the Watch List for the first time, citing AI training-data, geographical-indications, and customs-enforcement concerns.

On 2 April 2026 President Trump issued a Presidential Proclamation under Section 232 of the Trade Expansion Act of 1962 ("Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States") imposing a 100% ad valorem tariff on imports of patented pharmaceutical products listed in the FDA Orange Book and Purple Book, together with the active pharmaceutical ingredients (APIs) and key starting materials used to make them. The base rate takes effect at 12:01 a.m. EDT on 31 July 2026 for the 17 manufacturers identified in Annex III, and on 29 September 2026 for all other companies. The proclamation adopts findings of the Section 232 investigation initiated by the Department of Commerce on 14 April 2025 into pharmaceuticals and APIs as a national- security supply-chain risk. The instrument is structured around a multi-tier rate ladder rather than a flat tariff: concessionary 15% rates for EU/Japan/South Korea/Switzerland/Liechtenstein under reciprocal-deal tracks, 10% for the UK with a pathway to 0% under the pending UK pharmaceutical agreement, a "+20%" surcharge for companies operating under a Commerce-approved onshoring plan (until 2 April 2030), and a 0% pathway for companies that combine an approved onshoring plan with an MFN-pricing agreement with HHS (until 20 January 2029). Generics, biosimilars and their ingredients, orphan drugs, nuclear medicines, plasma-derived therapies, fertility treatments, and cell/gene therapies are carved out.

Premier Li Qiang signed State Council Order No. 834 on 31 March 2026 promulgating the "Provisions on Industrial Chain and Supply Chain Security" (18 articles), adopted at the State Council executive meeting on 13 March 2026 and effective on the date of publication. The Provisions are the first dedicated PRC administrative regulation on industrial- and supply-chain security and consolidate authorities drawn from the National Security Law, Foreign Relations Law, Anti-Foreign Sanctions Law, and Foreign Trade Law into a horizontal defensive framework. They establish a cross-agency coordination mechanism spanning roughly 15 central departments (industrial, security, cyberspace, customs and financial regulators) plus provincial governments; create a security-investigation system; and vest broad countermeasure authority over both foreign states (Article 14 — import/export prohibitions and special levies) and foreign organisations and individuals (Article 15 — import/export bans, China-investment bars, transaction prohibitions, entry bars and revocation of work or residence permits, with extension to effectively-controlled subsidiaries). The Provisions also impose compliance, information-sharing, strategic-reserve and emergency-response obligations on PRC organisations and individuals, and authorise requisition, mandated production and directed transportation in the event of supply-chain disruption.

On 1 May 2026 the trade pillar of the EU-Mercosur Partnership Agreement (the "Interim Trade Agreement", iTA) entered provisional application between the European Union and the four Mercosur states — Argentina, Brazil, Paraguay and Uruguay — following its publication in the EU Official Journal on 27 February 2026 alongside the broader EU-Mercosur Partnership Agreement (EMPA). The iTA covers goods (eliminating duties on more than 90% of bilateral trade over a transition period including immediate cuts on cars, pharmaceuticals, wine and olive oil), services, government procurement at federal and state level, intellectual property (344 EU geographical indications protected), SPS/TBT disciplines, and a sustainability chapter. Mercosur receives tariff-rate quotas on agri-food exports (beef, poultry, sugar, ethanol, honey). Provisional application proceeds pending full ratification of EMPA by the Council, European Parliament and all EU national parliaments and a pending CJEU opinion; only the trade pillar applies provisionally.

President Trump signed a Presidential Proclamation on 20 February 2026 invoking Section 122 of the Trade Act of 1974 (19 U.S.C. § 2132) to impose a temporary 10% ad-valorem import surcharge on articles imported into the United States, effective 12:01 a.m. EST on 24 February 2026. The proclamation was issued within hours of the US Supreme Court's 20 February 2026 ruling in Learning Resources, Inc. v. Trump, which held that the International Emergency Economic Powers Act (IEEPA) does not authorize the president to set tariffs and vacated the IEEPA-based reciprocal-tariff regime previously in effect. The Section 122 surcharge is statutorily limited to 150 days (terminates 24 July 2026 absent Congressional extension) and the statute caps any such surcharge at 15% ad valorem. Goods qualifying as USMCA originating from Canada or Mexico are exempt; CAFTA-DR textile/apparel articles meeting specified rules of origin are exempt; and a substantial product-exception list excludes critical minerals, energy products, certain pharmaceuticals, electronics, vehicles, aerospace products, specified agricultural goods, and goods already subject to Section 232 duties (the Section 122 duty does not stack on Section 232).

On 12 February 2026, Ambassador Jamieson Greer of the Office of the United States Trade Representative oversaw the signing of the US-Taiwan Agreement on Reciprocal Trade (ART) in Washington, DC. The instrument was signed under the auspices of the American Institute in Taiwan (AIT) and the Taipei Economic and Cultural Representative Office in the United States (TECRO). Headline terms: (i) US IEEPA reciprocal-tariff rate on Taiwan reduced from 20% to 15% and Section 232 auto-parts/timber/lumber rate cut from 25% to 15%; (ii) Taiwan eliminates or reduces 99% of its tariff barriers on US goods, most immediately and the remainder phased over three years; (iii) Taiwan side commits ~USD 85bn in directed purchases through 2029 (USD 44.4bn LNG/crude, USD 15.2bn civil aircraft and engines, USD 25.2bn power equipment); (iv) sectoral chapters covering tariffs, non-tariff barriers, digital trade, economic security, and high-tech supply-chain resilience. Operationally linked to the 15 January 2026 AIT-TECRO Memorandum of Understanding on investment, under which Taiwan pledges USD 250bn in direct Taiwanese-enterprise investment in the US plus USD 250bn in Taiwan-government credit guarantees (USD 500bn total) to fund US-side industrial parks/clusters in advanced semiconductors, energy, and AI manufacturing. Entry into force is conditional on Taiwan's Legislative Yuan completing its review.

On 6 February 2026 Presidents Trump and Modi announced a framework for an Interim Trade Agreement that resets the bilateral tariff posture installed in 2025. Two operative instruments: (i) an executive order signed 6 February eliminating, effective 7 February 2026, the additional 25% IEEPA "Russian-oil" duty on Indian imports imposed by EO 14329 (27 August 2025), conditional on India's commitment to cease buying Russian crude and to expand defence cooperation; and (ii) reduction of the EO 14257 reciprocal-tariff rate on India from 25% to 18% on listed product categories (textiles and apparel, leather and footwear, plastics and rubber, organic chemicals, home décor, artisanal products, certain machinery), to take effect on finalisation of the Interim Agreement. India commits to eliminate or reduce tariffs on all US industrial goods and a wide range of agricultural products (DDGs, red sorghum, tree nuts, fresh and processed fruit, soybean oil, wine, spirits) and to purchase >USD 500bn of US energy, ICT, coal, aircraft and aircraft parts, and precious-metals products over five years. The framework also commits the parties to negotiating "robust, ambitious, and mutually beneficial digital trade rules" and to addressing non-tariff barriers in medical devices, ICT import licensing, and food/agricultural standards. US tariff reductions on Indian generic pharmaceuticals, gems, diamonds, aircraft parts, and certain automotive components are flagged as contingent on completion of the full Interim Agreement.

On 27 January 2026 the European Union and India announced the conclusion of negotiations on a comprehensive Free Trade Agreement at the EU-India summit hosted at Hyderabad House in New Delhi, attended by PM Narendra Modi, Commission President Ursula von der Leyen and Council President António Costa. The deal — described by both leaders as the "mother of all deals" — covers ~25% of world GDP and ~2 billion people. The EU eliminates duties on 91% of tariff lines (covering 99.3% of bilateral trade by value); India eliminates duties on 86% of lines (covering 96.6% by value). Headline cuts include Indian tariffs on EU wines (150% → 75% at entry into force, falling to 20%), olive oil (45% → 0% over five years) and processed agri-food (up to 50% eliminated); EU tariffs are reduced/eliminated on Indian textiles, leather/footwear, gems and jewelry, marine products, tea, coffee, spices and certain agricultural and steel products. The agreement still requires Council adoption, European Parliament consent and approval by India's Union Council of Ministers; entry into force is expected in early 2027. Companion instruments concluded at the same summit include an EU-India Security and Defence Partnership and a Mobility and Migration Agreement.

On 14 January 2026 President Trump issued a Presidential Proclamation under Section 232 of the Trade Expansion Act of 1962 titled "Adjusting Imports of Processed Critical Minerals and Their Derivative Products into the United States". Unlike the parallel 14 January 2026 semiconductor proclamation and the subsequent April 2026 pharmaceutical proclamation, the PCMDP proclamation does NOT immediately impose tariffs. Instead it directs the Secretary of Commerce and the U.S. Trade Representative to jointly negotiate bilateral and plurilateral supply agreements with trading partners, with an initial 180-day status report due 13 July 2026. The proclamation reserves residual authority to impose tariffs if negotiations fail or prove ineffective, and explicitly contemplates "price floors" on PCMDP imports as a negotiated instrument.

Section 851 of the FY 2026 National Defense Authorization Act (P.L. 119-60), signed December 18, 2025, prohibits US federal agencies from procuring biotechnology equipment or services from designated "biotechnology companies of concern" (BCCs), and bars federal contractors from using such equipment/services in work performed under federal contracts, grants, or loans. The final enacted text ties initial BCC designations to DoD's existing §1260H Chinese-military-company list (which currently includes BGI and MGI, but not WuXi AppTec or WuXi Biologics) and directs OMB to designate additional BCCs within one year of enactment; operational prohibitions activate 60-90 days after FAR revision, with a five-year grandfather period for pre-existing contracts — enforcement is expected to begin in 2027-28. The legislation is the successor to H.R.8333 (118th Congress, House-passed September 2024 but stalled in the Senate before adjournment) and represents the first enacted US federal-procurement biotech-supply-chain-resilience statute.

On 16 December 2025 the European Commission adopted in Strasbourg the Proposal for a Regulation establishing a framework of measures for strengthening the Union's biotechnology and biomanufacturing sectors particularly in the area of health — the "European Biotech Act" (COM(2025) 1022 final). The proposal is the third axis of the EU's pharma/biotech industrial-policy stack alongside the Critical Medicines Act (filed: 2025-03-11-eu-critical-medicines-act-proposal) and the US Section 232 pharmaceuticals track (filed: 2026-04-02-us-section-232-pharmaceutical-proclamation), and is explicitly designed to keep biotech innovation, investment, and biomanufacturing capacity in Europe in the face of US/China competitiveness pressure. Core instruments: (1) statutory recognition for "Health Biotechnology Strategic Projects" (HBSPs) and "High-Impact" HBSPs eligible for accelerated permitting via a single national contact point, plus administrative/technical/ financial support; (2) regulatory sandboxes for novel biotech and biomanufacturing modalities; (3) a 12-month Supplementary Protection Certificate extension for qualifying biotech and advanced-therapy medicines; (4) targeted simplification of existing EU life-sciences acquis (clinical-trial timelines, risk-proportionate requirements); (5) an EU Health Biotechnology Investment Pilot co-developed with the EIB Group, paired with a EUR 10bn 2026-27 EIB-Commission financing initiative; (6) biosecurity safeguards including a list of "biotechnology products of concern" and mandatory built-in screening for benchtop nucleic-acid synthesis devices. A second tranche covering industrial biotechnologies and biomanufacturing outside health is expected later in 2026.

In the early hours of 11 December 2025 the Council of the EU and the European Parliament reached provisional political agreement in trilogue on the "EU Pharma Package" — the revised pharmaceutical Regulation (COM 2023/0131) and Directive (COM 2023/0132) — the most significant overhaul of EU pharmaceutical legislation in over two decades. The package replaces Directive 2001/83/EC (Community Code on medicinal products for human use) and Regulation (EC) 726/2004 (the EMA Regulation), and consolidates the orphan-medicine (Regulation 141/2000) and pediatric-medicine regulations into a single framework. Headline provisions: (i) a new "8+1(+1)(+1)" IP-incentive architecture — 8 years of regulatory data protection plus 1 year of market protection, with up to two additional 12-month extensions for products addressing unmet medical need or new active substances meeting comparative-trial conditions, capped at 11 years total; (ii) an EU-wide list of critical medicines under enhanced governance via the Medicines Shortages Steering Group (MSSG) and an EMA "list of critical shortages in the EU"; (iii) mandatory shortage-prevention plans on marketing-authorisation holders for prescription medicines and Commission-designated products; (iv) modernisation of clinical-trial requirements, environmental-risk assessment, antimicrobial stewardship, and a transferable-exclusivity-voucher (TEV) regime to incentivise novel antibiotic R&D. The COREPER I committee endorsed the compromise text on 6 March 2026 and final adoption by Parliament and Council is expected during summer 2026, with the regulatory framework becoming applicable in 2028.

On 13 November 2025, the United States and the Republic of Korea released a Joint Fact Sheet reaffirming the July 2025 announcement of the Korea Strategic Trade and Investment Deal — the first standalone US-Korea trade-and-investment agreement since the 2012 KORUS FTA. USTR issued the implementing Federal Register notice (90 FR 55964, Notice 2025-21940) on 3 December 2025, effective 4 December 2025, with retroactive HTSUS application to 1 November 2025 for autos and auto parts and to 14 November 2025 for reciprocal-tariff goods, timber, lumber, derivatives, and certain aircraft and aircraft parts. On the US tariff side: (i) the country-specific IEEPA reciprocal tariff on Korean originating goods is set at the higher of the KORUS FTA / MFN rate or 15% (parallel to the Japan and EU framework deals); (ii) the Section 232 tariffs on autos, auto parts, timber, lumber and wood derivatives are reduced to 15% (no incremental duty when the pre-existing KORUS/MFN rate already meets or exceeds 15%); (iii) Korean exports of qualifying goods on the Potential Tariff Adjustments for Aligned Partners (PTAAP) list are exempt from reciprocal tariffs (covering generic pharmaceuticals and unavailable natural resources); (iv) Section 232 pharmaceuticals capped at 15%; semiconductors granted MFN-style "no less favourable" treatment in any future sectoral deal. On the investment side, Korea commits to a USD 350bn package: USD 150bn into US shipbuilding ("Approved Investments") plus USD 200bn into US strategic industries via a separate Strategic Investments MOU, with annual currency-funding cap of USD 20bn. Non-tariff commitments include streamlined US biotech approvals on the Korean side, US meat and cheese market access, fair treatment for US digital services, removal of Korea's 50,000-unit cap on US vehicles meeting FMVSS, and joint WTO support for the moratorium on customs duties on electronic transmissions.

On 5 February 2026, USTR Ambassador Jamieson Greer and Argentine Foreign Minister Pablo Quirno signed in Washington the United States-Argentina Agreement on Reciprocal Trade and Investment (ARTI), formalising the framework jointly announced on 13 November 2025. The agreement is the first standalone bilateral trade-and-investment instrument concluded by the second Trump administration and the first FTA-style agreement signed under the post-IEEPA reciprocal-tariff architecture (Executive Order 14257, "Liberation Day"). On the US side, the ARTI sets out three tariff schedules: (i) Schedule 2A suspends additional reciprocal tariffs under EO 14257 for specified Argentine-origin goods (covering "unavailable natural resources" and non-patented pharmaceutical inputs); (ii) Schedule 2B grants a zero additional reciprocal tariff for designated Argentine agricultural products under EO 14360; and (iii) caps additional ad-valorem duties on other goods at 10% above MFN rates, inclusive of IEEPA reciprocal tariffs. On the Argentine side, illustrative tariff-rate quotas include duty-free access for 80,000 MT of US beef in calendar year 2026, 1,000 MT for cheese, 870 MT for almonds, 40 MT in-shell + 40 MT shelled for pistachios, 80,000 litres for wine (<2 L bottles), and preferential treatment for 10,000 motor vehicles meeting defined technical parameters. Argentina additionally commits to broader preferential market access on medicines, chemicals, machinery, information-technology products, medical devices, and a wide range of agricultural goods, alongside IP-enforcement upgrades (counterfeit/pirated-goods enforcement, patentability criteria, patent-backlog reduction, geographical indications) and investment-facilitation commitments that align Argentina's regime with US-preferred standards on regulatory cooperation, labour and environment.

China's State Council promulgated Order No. 818 on 28 September 2025 (effective 1 May 2026), establishing a comprehensive dual-track regulatory framework for biomedical new technologies — defined as techniques operating at the cellular or molecular level not yet clinically applied in China, covering cell therapy, gene editing, CAR-T, stem-cell, xenotransplantation, brain-computer interfaces, and nucleic-acid therapies. The regulation creates two parallel pathways: a traditional NMPA drug/device registration route and a new NHC-supervised clinical-research-to-commercialization track applicable to highly personalised or rare-disease therapies meeting staged safety and efficacy thresholds. Commercialisation under the NHC track is initially restricted to accredited Grade-3A medical institutions without full NMPA marketing approval, potentially accelerating patient access for qualifying technologies by 5–8 years relative to the standard registration pathway.

On 26 September 2025, Japan's Minister of Finance Katsunobu Kato announced the establishment of the Japan Strategic Investment Facility, a JBIC-administered financing vehicle operationalising the USD 550bn investment pledge from the July 2025 US-Japan tariff and investment agreement. The facility launched 1 October 2025 and runs through March 2029, supporting the overseas expansion of Japanese companies across nine economic-security sectors: semiconductors, pharmaceuticals, steel, shipbuilding, critical minerals, aviation, energy, automobiles, and AI/quantum technology. Funding draws on three sources — dollar-denominated JBIC bonds, yen-denominated Japanese government loans to JBIC, and a "supplemental" transfer from Japan's USD 1.324tn foreign-currency reserves — with private-sector loans and NEXI-backed loan guarantees supplementing JBIC's own financing.

South Korea's National Assembly passed an amendment to the Korea Development Bank (KDB) Act on 2025-08-27 (428th session, 3rd plenary sitting, 164-1 with 164 votes in favour of 165 cast), raising KDB's statutory capital ceiling from KRW 30 trillion to KRW 45 trillion and creating a new "Advanced Strategic Industry Fund" inside KDB. The fund is capitalised at KRW 50 trillion or more over five years via low-rate government-guaranteed bonds and is earmarked for the ten officially designated advanced strategic industries (AI, semiconductors, bio/vaccines, defense, robotics, hydrogen, secondary batteries, displays, future mobility) via cheap loans and equity investment. KDB intends to use the fund as seed capital for a wider "National Growth Fund" that blends in private and pension capital to reach KRW 100 trillion+ in total strategic-industry financing over five years.

Act L of 2025 (2025. évi L. törvény) is the Hungarian National Assembly statute that elevates a set of war-emergency government decrees — including the foreign-investment screening regime previously embedded in Government Decree 561/2022 — to permanent statutory level. Promulgated in Magyar Közlöny and entered into force on 19 August 2025, the Act preserves Hungary's "Second Regime" of FDI screening operating in parallel with the General Regime (which implements EU Reg 2019/452 since 2019). The Second Regime applies to a broad set of strategic sectors — energy, transport, communications, telecoms, pharmaceuticals, food processing, defence, financial services and healthcare — and requires approval from the Minister of National Economy for qualifying acquisitions (direct or indirect majority, ≥5% interest, ≥3% in listed companies, or ownership/operation of strategic infrastructure) where transaction value reaches HUF 350 million (~EUR 890,000). Notification is due within 10 days of signing; the MoE originally had 30 business days (extendable +15 calendar days). The Act also entrenches the Hungarian state right of first refusal on photovoltaic generation companies (NACE 35.11'08, excluding sub-50 kVA household installations), exercised through MNV Zrt. The Special Regime is structurally distinct from the General Regime and represents Hungary's peer to the German AWG §§55-62, French Décret 2014-479, Dutch Wet Vifo, and Italian Golden Power. Amended by Act XCIII of 2025 (in force 17 December 2025), which extended the MoE screening deadline to 45 business days and excluded bank-financing security arrangements from notification.

On 13 August 2025 President Trump signed an Executive Order ("Ensuring American Pharmaceutical Supply Chain Resilience by Filling the Strategic Active Pharmaceutical Ingredients Reserve", Federal Register Doc. 2025-15823, published 19 August 2025) directing the HHS Assistant Secretary for Preparedness and Response (ASPR) to refill and operationalise the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR). Within 30 days, ASPR must compile an initial list of 26 essential drugs, account for available funding, and acquire and maintain a six-month supply of the corresponding APIs. Within 90 days, ASPR must deliver an expanded list of up to 86 essential medicines and medical countermeasures plus a plan to source those APIs from domestic manufacturers, and within 120 days (subject to appropriations) ready the existing SAPIR repository and submit a proposal and cost estimate for opening a second repository. The order prioritises domestically manufactured APIs in federal procurement and reserve build-out and directs interagency coordination across HHS/ASPR, FDA, DoD (Industrial Base Fund / Defense Production Act Title III), and the Department of Commerce.

On 27 July 2025, President Trump and European Commission President Ursula von der Leyen reached political agreement at Turnberry, Scotland, on a Framework Agreement on Reciprocal, Fair and Balanced Trade. The framework was formalised in a Joint Statement published on 21 August 2025 by the White House and DG TRADE. The deal establishes a 15% all-inclusive (MFN + Section 232) US tariff ceiling on the vast majority of EU originating goods — including autos, pharmaceuticals, semiconductors, lumber, and chemicals — replacing the threatened 20-30% reciprocal tariff trajectory under EO 14257 (April 2025). Steel and aluminium are excluded from the 15% ceiling and remain at the 50% Section 232 rate pending negotiation of a quota solution. In return, the EU commits to: (i) eliminate tariffs on all US industrial goods, (ii) preferential market access for a wide range of US agricultural and seafood products, (iii) suspension of its rebalancing countermeasures under Reg 2025/778 (suspension effective 7 August 2025), (iv) expected energy offtake of $750bn (LNG, oil, nuclear) through 2028, (v) at least $40bn in US AI chip purchases, and (vi) facilitation of $600bn in additional EU corporate investment into the US through 2028. Effective from 1 September 2025, the US applies MFN-only treatment (no 15% top-up) to: aircraft and parts, generic pharmaceuticals and ingredients, chemical precursors, cork, and certain unavailable natural resources. The framework is not legally binding but anchors the bilateral architecture; it is the largest-economy ART-programme deal alongside US-UK, US-Japan, US-Korea, US-Taiwan, and US-Indonesia.

President Trump signed Executive Order 14273, "Delivering Most- Favored-Nation Prescription Drug Pricing to American Patients", on 12 May 2025. The EO directs HHS, USTR, and Commerce to pursue mechanisms (negotiation targets, importation pathways, and trade-policy levers) to bring the prices Americans pay for innovative prescription drugs into alignment with the *lowest* prices paid by other comparably-developed nations — the "most-favored-nation" (MFN) benchmark. Unlike the Biden-era Inflation Reduction Act drug-price-negotiation provisions (which apply to a handful of Medicare Part D drugs), the EO applies pressure across the broader pharmaceutical pricing surface. As of April 2026, 17 major pharmaceutical manufacturers (incl. Eli Lilly, Pfizer, Bristol-Myers Squibb, AbbVie, Merck, AstraZeneca, Regeneron) have signed bilateral agreements bringing US drug prices toward the international- benchmark level for selected medications.

On 1 February 2025, Finance Minister Nirmala Sitharaman announced the National Manufacturing Mission (NMM) in the Union Budget 2025-26 as a horizontal umbrella framework extending the 2014 "Make in India" architecture across small, medium and large industries. The mission rests on five focal areas: (i) ease and cost of doing business; (ii) a future-ready workforce for in-demand jobs; (iii) a vibrant and dynamic MSME sector; (iv) availability of technology; and (v) quality manufacturing. It will deliver policy support, execution roadmaps, and a governance/monitoring framework binding central ministries with states. NMM specifically commits to building a clean-tech manufacturing ecosystem with explicit coverage of solar PV cells, EV batteries, motors and controllers, electrolysers, wind turbines, very-high-voltage transmission equipment, and grid-scale batteries — i.e., the full hardware stack for India's Panchamrit (500 GW non-fossil by 2030), FAME-III EV ramp, and National Green Hydrogen Mission. NMM is the first horizontal Indian manufacturing-mission instrument in the IPTM register; existing IND entries are sector-specific PLIs (electronics, batteries, steel, semiconductors) and the National Critical Mineral Mission. Operational rollout flows through subsequent Cabinet-level scheme approvals (e.g. Biopharma SHAKTI ₹10,000 cr, Chemical Parks ₹600 cr in BE 2026-27); the mission itself does not carry a single headline outlay because it is the framework rather than an instrument.

Switzerland's Federal Council promulgated the Verordnung über die Mindestbesteuerung grosser Unternehmensgruppen (Mindestbesteuerungsverordnung, MindStV; French: OIMin), SR 642.161, AS 2023 841, on 22 December 2023, with effect from 1 January 2024. The ordinance enacts a 15% Qualified Domestic Minimum Top-up Tax (QDMTT — Ergänzungssteuer) on Swiss constituent entities of MNE groups with consolidated annual revenue ≥ EUR 750 million, enacted under the temporary constitutional authority granted by Swiss voters in a popular referendum on 18 June 2023 (78.5% yes, Art. 129a BV). The Income Inclusion Rule (IIR) and Undertaxed Profits Rule (UTPR) were deliberately deferred to subsequent ordinance amendments, targeting FY 2025 phasing. The Swiss Federal Tax Administration (ESTV / AFC) is the administering authority; first QDMTT returns and GloBE Information Returns due 30 June 2026.

Ireland's Screening of Third Country Transactions Act 2023 (Act No. 28 of 2023), signed into law on 31 October 2023 and commenced on 6 January 2025 via S.I. No. 651 of 2024, establishes Ireland's first-ever mandatory inbound FDI screening regime. The Act empowers the Minister for Enterprise, Tourism and Employment to assess, condition, or prohibit transactions by third-country investors (non-EU/EEA/Switzerland) exceeding a EUR 2 million cumulative threshold in targets operating across critical infrastructure, critical technologies, dual-use items, supply of critical inputs, sensitive personal data, and media freedom. A 90-day standstill period applies during Ministerial determination, with criminal sanctions and transaction-voiding powers available for non-compliance.

Malaysia's New Industrial Master Plan 2030 (NIMP 2030) is the fourth-edition national industrial master plan launched on 1 September 2023 by Prime Minister Anwar Ibrahim under the Ministry of Investment, Trade and Industry (MITI). Spanning seven years to 2030, NIMP 2030 adopts a mission-based approach with 4 missions, 21 strategies and 62 action plans, mobilising an RM95bn investment envelope (predominantly private-sector capital channelled through private equity and the capital markets). The plan targets a step-change in manufacturing-sector economic complexity, deeper local-industry linkages and expanded participation in global supply chains, with explicit numerical targets for the manufacturing sector's GDP contribution and annual growth by 2030.

Directive (EU) 2022/2555 of the European Parliament and of the Council of 14 December 2022 on measures for a high common level of cybersecurity across the Union (NIS 2 Directive), published OJ L 333, 27 December 2022, entered into force 16 January 2023. NIS2 repeals and substantially expands the 2016 NIS1 Directive (2016/1148), extending the scope from ~7 sectors to 18 enumerated essential and important sectors, imposing binding cybersecurity risk- management and incident-reporting obligations on covered entities, introducing board-level management accountability, and mandating Member State transposition by 17 October 2024. NIS2 is the structural EU statutory anchor for national cybersecurity frameworks across the bloc, operating alongside DORA (Reg 2022/2554) for financial-sector digital resilience and CRA (Reg 2024/2847) for product cybersecurity.

On 18 October 2022, Crown Prince Mohammed bin Salman launched Saudi Arabia's National Industrial Strategy (NIS) under the Vision 2030 umbrella, with delivery led by the Ministry of Industry and Mineral Resources (MIM). The strategy prioritises 118 segments within 12 industrial sub-sectors (including downstream chemicals, automotive, aerospace, machinery, and metals), identifies more than 800 investment opportunities estimated at ~USD 266bn, and sets binding 2030/2035 targets: triple manufacturing GDP by 2030, raise industrial exports to SAR 557bn (~USD 148bn), bring cumulative additional investment to SAR 1.3 trillion, and grow factories from ~10,000 to ~36,000 by 2035. NIS sits alongside the National Industrial Development and Logistics Program (NIDLP, 2019) and the Public Investment Fund's strategic-sector mandates as the third leg of the Kingdom's non-oil-economy build-out.

Russian Government Resolution No. 506 of 29 March 2022, signed by Prime Minister Mikhail Mishustin and effective 30 March 2022, authorises the Ministry of Industry and Trade (Minpromtorg) to designate categories of goods exempt from articles 1252(4), 1359(6) and 1487 of the Russian Civil Code on national/regional exhaustion of trademark and other intellectual- property rights. Followed by Minpromtorg Order No. 1532 of 19 April 2022 publishing an initial list of 55 goods categories and named brands — including pharmaceuticals, electronics, automotive parts, mineral fuels, industrial chemicals, paper, textiles, base metals, and consumer goods — for which parallel (grey-market) imports without IP-holder consent are legalised. Designed as a sanctions-circumvention and supply-substitution instrument after the Western corporate exodus of March 2022; extended annually and most recently re-authorised through 31 December 2026.

On 22 March 2021, UAE Vice President and Prime Minister Sheikh Mohammed bin Rashid Al Maktoum launched Operation 300bn at Qasr Al Watan in Abu Dhabi — a 10-year national industrial strategy delivered by the newly created Ministry of Industry and Advanced Technology (MoIAT, established July 2020). The strategy targets raising the industrial sector's annual GDP contribution from AED 133bn (~USD 36bn) to AED 300bn (~USD 82bn) by 2031, lifting R&D spend from AED 21bn to AED 57bn (1.3% → 2% of GDP), and supporting more than 13,500 industrial SMEs through an AED 30bn (~USD 8.2bn) Emirates Development Bank (EDB) financing portfolio. Eleven priority sub-sectors are organised into three baskets: Stimulating Growth (food/beverage, pharmaceuticals, electrical equipment), Advanced Manufacturing (petrochemicals, rubber/plastics, machinery), and Industries of the Future (hydrogen, medical technology, space technology).

The Department of Pharmaceuticals notified the Production Linked Incentive (PLI) Scheme for Promotion of Domestic Manufacturing of Critical Key Starting Materials (KSMs), Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) on 21 July 2020 via Gazette Notification, with an outlay of Rs 6,940 crore (~USD 920m) over FY 2020-21 to FY 2027-28. The scheme covers 41 identified critical bulk-drug products across four target segments — fermentation-based (Key Fermentation; Niche Fermentation) and chemical synthesis-based (Key Chemical Synthesis; Niche Chemical Synthesis) — paying 20% incentive on incremental sales for fermentation-based products (years 1-4) tapering to 15% (year 5) and 5% (year 6), and a flat 20% over 5 years for chemically-synthesised products. The stated objective is to reduce India's ~70% bulk-drug import dependence on China by establishing greenfield domestic manufacturing capacity with at least 90% domestic value addition for fermentation products and 70% for chemical-synthesis products.

The modern French FDI-screening regime is codified in Code monétaire et financier (CMF) Art. L151-1 to L151-7, substantially restructured by Loi PACTE n° 2019-486 du 22 mai 2019 (Art. 152-158) and operationalised by Décret n° 2019-1590 du 31 décembre 2019 (in force 1 April 2020) with implementing Arrêté du 31 décembre 2019. The regime requires prior authorisation from DG Trésor for non-EU/EEA acquisitions reaching ≥25% of a French target's voting rights across 17 sensitive sectors enumerated in CMF Art. R151-3, and for ≥10% acquisitions in listed-company targets (threshold made permanent by Décret 2023-1293 from 1 January 2024, having been originally introduced during COVID-19 by Décret 2020-892). Approximately 310 notifications are received annually; the regime closes the last major G7 EU-member-state FDI-screening parent-statute gap after DE AWG §§55-62, IT Golden Power DL 21/2012, NL Wet Vifo, UK NSI Act 2021, US CFIUS, JP FEFTA, AU FATA, and CH IPG.

The Trade Expansion Act of 1962 (Pub. L. 87-794, 76 Stat. 872), signed into law by President Kennedy on 11 October 1962 and codified at 19 U.S.C. §§ 1801–1991, is the foundational US statute granting the executive branch broad authority to negotiate tariff reductions and, critically via Section 232 (19 U.S.C. § 1862), to adjust imports of any article found by the Secretary of Commerce to threaten to impair national security. Section 232 empowers the President — on receipt of a Commerce Department affirmative national-security finding — to impose tariffs, quantitative restrictions, or other import-adjustment measures without congressional approval or WTO-required safeguard procedures. From 1962 to the Trump Administration's 2018–2026 wave of Section 232 Proclamations, the authority was invoked primarily for petroleum and machine-tool imports; since 2018 it has become the legal vehicle for national-security tariffs on steel, aluminum, automobiles, copper, timber, critical minerals, semiconductors, and pharmaceuticals, with 19+ IPTM-filed implementing instruments citing Pub. L. 87-794 / 19 U.S.C. § 1862 as their statutory parent.

The Defense Production Act of 1950 (Pub. L. 81-774, 64 Stat. 798, codified at 50 U.S.C. §§4501–4568) is the foundational US statute governing wartime and emergency industrial mobilization. Signed by President Truman on 8 September 1950 during the Korean War, the Act empowers the President to compel industrial priority-rated ordering (Title I / DPAS), authorize direct investment in domestic production capacity for critical industries (Title III), and conduct investment security review (Title VII, precursor to CFIUS). Reauthorized approximately 50 times, most recently extended through September 2025 by Pub. L. 115-263 (2018) and further extended under NDAA FY2026; it has been invoked by every Administration since 1950 and has accelerated dramatically since 2020 to target critical-minerals processing, semiconductor manufacturing, battery supply chains, biopharmaceuticals, and energy infrastructure.